Palau was founded in 2006, with an initial private placement investment of approximately €40 million. Our investors include Grupo Uriach (who retains the majority stake), Caixa Catalunya, Caja Duero, Najeti Capital, Andosins Capital and Palau’s senior management.

Our business philosophy is designed to minimize risk by targeting needs that are currently not adequately addressed by existing drugs. Once a target is identified, we move as quickly as possible to bring an effective solution to market, using a streamlined process that helps maximize returns without compromising product quality.

Our track record, rapid development process, and focus on identified unmet patient needs are designed to provide value to investors by decreasing risk and increasing the likelihood of a timely return on investment. For more information about investment opportunities, Contact Us.

	Member	Representing	Position
	Enrique Uriach	Grupo Uriach	Chairman
	Javier Uriach	Grupo Uriach	Member
	Joaquín Uriach	Grupo Uriach	Member
	Juan Uriach	Grupo Uriach	Member
	Marta Uriach	Grupo Uriach	Member
	Xavier Auguets	Caixa Catalunya	Member
	Herwann Mahaud	Caja Duero	Member
	Josep Vicens	Andosins Capital	Member
	Thibaud Durand	Najeti Capital	Member